Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biochemical Pharmacology

• Publication date

  2005-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.BCP.2005.05.015PMID 15978547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomic structure, chromosome location, and alternative splicing of the humanNKG2A gene

  2007cited by this paper
• TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling1

  2004cited by this paper
• Cyclooxygenase‐2 and 5‐lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy

  2003cited by this paper
• Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

  2003cited by this paper
• EP2 and EP4 prostanoid receptor signaling.

  2003cited by this paper
• Differential expression of natural killer receptors on Vdelta1 gammadelta T cells in HIV-1-infected individuals.

  2003cited by this paper
• Role That Each NKG2A Immunoreceptor Tyrosine-Based Inhibitory Motif Plays in Mediating the Human CD94/NKG2A Inhibitory Signal

  2002cited by this paper
• NK Cell CD94/NKG2A Inhibitory Receptors Are Internalized and Recycle Independently of Inhibitory Signaling Processes

  2002cited by this paper
• Prostaglandins as modulators of immunity.

  2002cited by this paper
• Viral and Bacterial Infections Induce Expression of Multiple NK Cell Receptors in Responding CD8+ T Cells1

  2002cited by this paper
• Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.

  2001cited by this paper
• Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse.

  2001cited by this paper
• Activation of the Cooh-Terminal Src Kinase (Csk) by Camp-Dependent Protein Kinase Inhibits Signaling through the T Cell Receptor

  2001cited by this paper
• Expression of CD94 and NKG2 molecules on human CD4+ T cells in response to CD3‐mediated stimulation

  2001cited by this paper
• Induction of cyclooxygenase‐2 expression during HIV‐1‐infected monocyte‐derived macrophage and human brain microvascular endothelial cell interactions

  2000cited by this paper
• Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1

  2000cited by this paper
• Increased expression of non‐functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients

  2000cited by this paper
• Differential expression of CD28 and CD94 / NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node

  2000cited by this paper
• Specificity in the cAMP/PKA signaling pathway. differential expression, regulation, and subcellular localization of subunits of PKA.

  2000cited by this paper
• Specificity in the cAMP/PKA signaling pathway. Differential expression,regulation, and subcellular localization of subunits of PKA.

  2000cited by this paper
• Dap10 and Dap12 Form Distinct, but Functionally Cooperative, Receptor Complexes in Natural Killer Cells

  2000cited by this paper
• Transforming growth factor‐β‐induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes

  1999cited by this paper
• Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.

  1999cited by this paper
• CD28‐negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients

  1999cited by this paper
• An activating immunoreceptor complex formed by NKG2D and DAP10.

  1999cited by this paper
• Expression of killer inhibitory receptors on cytotoxic cells from HIV‐1‐infected individuals

  1999cited by this paper
• Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells.

  1999cited by this paper
• Phosphoantigen activation induces surface translocation of intracellular CD94/NKG2A class I receptor on CD94− peripheral Vγ9 Vδ2 T cells but not on CD94− thymic or mature γ δ T cell clones

  1998cited by this paper
• HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells.

  1998cited by this paper
• HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.

  1998cited by this paper
• Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.

  1998cited by this paper
• Expression of cyclooxygenase-2 in human lung carcinoma.

  1998cited by this paper
• Association of DAP12 with activating CD94/NKG2C NK cell receptors.

  1998cited by this paper
• Phosphoantigen activation induces surface translocation of intracellular CD94/NKG2A class I receptor on CD94- peripheral Vgamma9 Vdelta2 T cells but not on CD94- thymic or mature gammadelta T cell clones.

  1998cited by this paper
• Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures.

  1998cited by this paper
• Protein kinase A type I antagonist restores immune responses of T cells from HIV‐infected patients

  1998cited by this paper
• The CD94 and NKG2‐A C‐type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules

  1997cited by this paper
• Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: impairment of specific cytolytic functions.

  1997cited by this paper
• NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell Receptor

  1997cited by this paper
• Expression of cyclooxygenase-2 in human gastric carcinoma.

  1997cited by this paper
• The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer

  1996cited by this paper
• Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits.

  1996cited by this paper
• Molecular characterization of human CD94: A type II membrane glycoprotein related to the C‐type lectin superfamily

  1995cited by this paper
• Novel (Rp)-cAMPS Analogs as Tools for Inhibition of cAMP-kinase in Cell Culture

  1995cited by this paper
• Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4+CD8+ T lymphoblasts.

  1995cited by this paper
• Transforming growth factor β1 augments mitogen‐induced prostaglandin synthesis and expression of the TIS10/prostaglandin synthase 2 gene both in swiss 3T3 cells and in murine embryo fibroblasts

  1994cited by this paper
• Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes.

  1993cited by this paper
• Targeting of T lymphocytes against egf‐receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross‐linking for t‐cell activation

  1993cited by this paper
• Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets.

  1992cited by this paper
• The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response.

  1988cited by this paper

• Cytotoxic T Cells: Kill, Memorize, and Mask to Maintain Immune Homeostasis

  2025cites this paper
• Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4

  2024cites this paper
• Treatment of cancer-associated fibroblast-like cells with celecoxib enhances the anti-cancer T helper 1/Treg responses in breast cancer

  2024cites this paper
• Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells

  2023cites this paper
• The role of PGE2 and EP receptors on lung's immune and structural cells; possibilities for future asthma therapy.

  2022cites this paper
• The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas.

  2022cites this paper
• Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer.

  2021cites this paper
• Systems approach reveals distinct and shared signaling networks of the four PGE2 receptors in T cells

  2021cites this paper
• Bioactive lipids, inflammation and chronic diseases.

  2020cites this paper
• Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19

  2020cites this paper
• Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro

  2019cites this paper
• Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer

  2018cites this paper
• Rôle de la protéine immuno-régulatrice PD-L1 sur le métabolisme des cellules tumorales

  2018cites this paper
• Role of prostanoids in gastrointestinal cancer.

  2018cites this paper
• Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis

  2017cites this paper
• Divide, Conquer, and Sense: CD8+CD28− T Cells in Perspective

  2017cites this paper
• Mise en évidence de biomarqueurs des cellules souches de la gelée de Wharton par modélisation dynamique des flux métaboliques : l’impact du vieillissement cellulaire

  2017cites this paper
• Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.

  2016cites this paper
• Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy.

  2016cites this paper
• Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: a potential target for 'two-in-one' cancer chemoimmunotherapeutics.

  2015cites this paper
• Innate Immune System and Preeclampsia

  2014cites this paper
• CYCLOOXYGENASE-2 AND HEPATOCELLULAR CARCINOMA: THE PROTEOMICS OF ASSOCIATION

  2013cites this paper
• An Inflammatory Mediator, Prostaglandin E2, in Colorectal Cancer

  2013cites this paper
• Tumor–microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma

  2013cites this paper
• Natural killer cells responsiveness to physical exercise: A brief review

  2013cites this paper
• Multilevel pharmacological manipulation of adenosine-prostaglandin E₂/cAMP nexus in the tumor microenvironment: a 'two hit' therapeutic opportunity.

  2013cites this paper
• Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology

  2013cites this paper
• Characterization of the PGE2 pathway in arthritis and inflammation : mPGES-1 as a therapeutic target

  2013cites this paper
• Proinflammatory and Immunoregulatory Roles of Eicosanoids in T Cells

  2013cites this paper
• NKG2 Subfamily C (KLRC)

  2012cites this paper
• Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy.

  2012cites this paper
• Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation.

  2011cites this paper
• Eicosanoids in cancer: new therapeutic targets in neuroblastoma

  2011cites this paper
• Aberrant PGE₂ metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells.

  2011cites this paper
• Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology

  2011cites this paper
• Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4

  2011cites this paper
• Eicosanoids and cancer

  2010cites this paper
• Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression.

  2010cites this paper
• Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells

  2010cites this paper
• Surgery as a Double-Edged Sword: A Clinically Feasible Approach to Overcome the Metastasis-Promoting Effects of Surgery by Blunting Stress and Prostaglandin Responses

  2010cites this paper
• The effect of two novel C-type lectins, Ba100 and Ba25, isolated from the venom of the puff adder, Bitis arietans on T lymphocyte proliferative responses

  2008cites this paper
• Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level.

  2008cites this paper
• The CD94/NKG2 family of receptors

  2006cites this paper